Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 2760Carcinoma, Non-Small-Cell Lung 2260Prostatic Neoplasms 1425Colorectal Neoplasms 1290Neoplasms 1258Multiple Myeloma 1084Lung Neoplasms 1048Neoplasm Metastasis 994Leukemia, Myeloid, Acute 984Lymphoma 900Melanoma 862Pancreatic Neoplasms 818Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 753Recurrence 750Leukemia 733Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Lymphoma, Large B-Cell, Diffuse 616Squamous Cell Carcinoma of Head and Neck 615Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 596Brain Neoplasms 592Carcinoma, Renal Cell 586Glioblastoma 572Rectal Neoplasms 563Myelodysplastic Syndromes 522Sarcoma 521Lymphoma, Follicular 516

Interventions

icotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × EGF-R Positive Non-Small Cell Lung Cancer × Clear all
NCT03749213 2018-11-21

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage â…¢A-N2 Non-small Cell Lung Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
36 enrolled
Thoracic

EGF-R Positive Non-Small Cell Lung Cancer

NCT03349203 2018-07-18

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
60 enrolled
Thoracic

EGF-R Positive Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡